Alkaline phosphatase engineered B cell therapy - Be Biopharma
Latest Information Update: 17 May 2024
At a glance
- Originator Be Biopharma
- Class Cell therapies; Gene therapies
- Mechanism of Action ALPL protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypophosphatasia